The Quantellect read.As of Nov 19, 2026, 12 active firms cover Acadia Healthcare Company Inc: 7 rate it Buy or better, 4 sit at Neutral, and 1 rate it Sell or worse, a neutral consensus. The target range is very wide, $13.00 to $40.00 (about 3.1x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $30.00 sits 20% below the current $37.58. The rating mix has stayed broadly stable, with Buy-side ratings easing from 8 to 7 over recent months. On the fundamentals, the Street sees revenue growth near 3% this year and 6% next, consensus EPS building from about $0.44 next quarter toward $2.04 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS12 active firms
Neutral
Strong Buy00%
Buy758%
Neutral433%
Sell18%
Strong Sell00%
Based on 12 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$30.00
-20.2% downside
Average target across 12 active firms as of Nov 19, 2026 vs $37.58 current
Highest Target$40.00
Average Target$30.00
Lowest Target$13.00
Detailed analyst forecasts for ACHC
Showing 1–12 of 12 named analysts shown · 12 active firms in the rating projection
As of Nov 19, 2026, 7 of 12 active firms rate ACHC a Buy (4 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ACHC EPS & revenue forecast
EPS · NEXT QUARTER
$0.44
Range $0.34 – $0.52 · 8 analysts · +18% YoY
Next period, 8 analysts expect Acadia Healthcare Company Inc to earn $0.44 a share (range $0.34 – $0.52), versus $0.37 a year earlier. Full-year consensus is $1.69, growing to $2.04 the year after.
REVENUE · NEXT QUARTER
$882.9M
Range $872.0M – $900.1M · 8 analysts · +3% YoY
Revenue is expected to reach $882.9M (range $872.0M – $900.1M), +3.0% year-over-year. Full-year consensus is $3.5B, rising to $3.7B next year.
Top analysts covering Acadia Healthcare Company Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ACHC.
#1
Ben Hendrix
RBC Capital · Rank #150
Buy
$31.00-17.5% to target
Overall win rate
44%
+ Follow
#2
Sarah James
Cantor Fitzgerald · Rank #159
Neutral
$39.00+3.8% to target
Overall win rate
37%
+ Follow
#3
Brian Tanquilut
Jefferies · Rank #280
Buy
$40.00+6.4% to target
Overall win rate
46%
+ Follow
#4
AR
A.J. Rice
UBS · Rank #365
Buy
$39.00+3.8% to target
Overall win rate
35%
+ Follow
#5
Andrew Mok
Barclays · Rank #385
Neutral
$32.00-14.8% to target
Overall win rate
39%
+ Follow
ACHC stock forecast FAQ
What is ACHC's average 12-month price target?+
The 12 active firms with a live target average $30.00 for Acadia Healthcare Company Inc over the next 12 months, ranging from a $40.00 high to a $13.00 low, as of Nov 19, 2026.
Is ACHC stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 12 active firms as of Nov 19, 2026, 7 rate it Buy or Strong Buy, 4 rate it Neutral, and 1 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ACHC?+
The Street-high target is $40.00 (Keybanc), and the Street-low is $13.00 (B of A Securities). The average of all 12 active-firm targets is $30.00.
How many active Wall Street firms cover ACHC?+
12 active firms have a recognized rating on Acadia Healthcare Company Inc as of Nov 19, 2026, and 12 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ACHC?+
Among analysts who currently cover ACHC, Ben Hendrix of RBC Capital has the strongest overall Quantellect track record (Rank #150). Their current call is Buy with a $31.00 target.
What is Acadia Healthcare Company Inc's projected EPS for next quarter?+
The consensus estimate is $0.44 per share (range $0.34 – $0.52) across 8 analysts. Full-year EPS is projected at $1.69, rising to $2.04 the following year.
How much revenue is Acadia Healthcare Company Inc expected to report next quarter?+
Consensus revenue is $882.9M (range $872.0M – $900.1M). Full-year revenue is projected at $3.5B, growing to $3.7B next year.
Have analysts been upgrading or downgrading ACHC lately?+
As of Nov 19, 2026, 7 of 12 active firms rate ACHC a Buy (4 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ACHC calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.